Zhangzhou pientzehuang pharmaceutical "curved" acquisition of Fujian cosunter pharmaceutical? The innovative drugs sector sees the reappearance of traditional chinese medicine industry players | Read the announcement quickly.

Fujian Cosunter Pharmaceutical announced that the Yuanshan Fund intends to become a shareholder with more than 5% stake in the company through a transfer payment of nearly 0.2 billion yuan. The partners of the Yuanshan Fund consist of a wholly state-owned company and a wholly-owned subsidiary of zhangzhou pientzehuang pharmaceutical, among which the investment from zhangzhou pientzehuang pharmaceutical is the largest limited partner in the fund.

cls.cn11:14 ET

yabao pharmaceutical group's two children's medicines revenue increased year-on-year, hydrochloride betahistine injection has not stopped the decline in revenue|direct hit earnings conference

yabao pharmaceutical group stated at the earnings conference that in the first three quarters of this year, the company's pediatric products revenue increased year-on-year. The company's secretary stated that while the revenue of levocetirizine hydrochloride injection decreased, the sales volume increased, and predicted that the 'income decline in the category will continue to narrow within the year'. yabao pharmaceutical group also provided explanations on the company's research pipeline progress, share buybacks, and other situations.

cls.cnNov 11 23:48 ET

The hottest summer Artemisia annua is not selling well chongqing taiji industry Q3 performance decreased by 70% | interpretations

In 2024, the national average temperature is the highest for the same period in history since 1961, but the sales volume of Chongqing Taiji Industry Huoxiang Zhengqi Oral Liquid decreased significantly in the third quarter, with a sharp drop in sales of the main product, leading to a year-on-year decline of over 70% in Chongqing Taiji Industry's profit in the third quarter.

cls.cnOct 24 09:59 ET

The rising prices of medicinal materials such as Atractylodes macrocephala are increasing costs. Jianmin Pharmaceutical Group's net income in Q3 fell by nearly fifty percent | Interpretations

①In the third quarter, jianmin pharmaceutical group's revenue was 0.872 billion yuan, a decrease of 8.83% year-on-year; net income was 82.2581 million yuan, a decrease of 49.46% year-on-year. ②The price of Atractylodes macrocephala has more than quadrupled in two years, and Atractylodes macrocephala is an important raw material for many of the company's main products. The increase in traditional chinese medicine prices has led to an increase in the company's procurement costs. ③Chairman He Qin of the company is currently unable to perform his duties as chairman due to personal health reasons.

cls.cnOct 18 10:17 ET

Shijiazhuang Yiling Pharmaceutical: The performance of respiratory products is affected by the high base in previous years and the high inventory in hospitals, related sales will gradually return to normal | Directly targeting the earnings conference

①Due to factors such as the high base of the previous year, high social inventory, and other impacts leading to a decrease in market demand for respiratory products, the performance has declined. In the future, sales of respiratory products in the company will gradually return to normal. ②The company expects that both cardiovascular and cerebrovascular block orders, as well as secondary products like Bazibu Shen and anxiety-relieving products, have good market potential. The future performance of new respiratory system products is also promising, and the company will continue to build its core product cluster.

cls.cnOct 15 11:13 ET

Wanbangde Pharmaceutical Holding Group: The financial director, who served for only eight months, resigned, and the chairman once again acted as the director. | Quick Read Announcement

①Tonight, wanbangde pharmaceutical holding group announced that the Chief Financial Officer Wang Tianfang has resigned, having served in this position for only 8 months; ②Chairman Zhao Shouming once again assumes the responsibilities of the Chief Financial Officer, having temporarily served in this role when the former CFO Zhao Junhui resigned in June 2022; ③Within three years, wanbangde pharmaceutical holding group's market cap has shrunk to only one-third.

cls.cnSep 29 11:29 ET